Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
ENALAPRILAT
SANDOZ CANADA INCORPORATED
C09AA02
ENALAPRIL
1.25MG
SOLUTION
ENALAPRILAT 1.25MG
INTRAVENOUS
2ML
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0118001001; AHFS:
APPROVED
2008-04-03
_ _ VASOTEC ® IV Page 1 of 30 PRODUCT MONOGRAPH Pr VASOTEC ® IV ENALAPRILAT INJECTION 1.25 MG/ML IN 2 ML VIALS ANGIOTENSIN CONVERTING ENZYME INHIBITOR Sandoz Canada Inc. Date of Revision: September 20, 2013 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 SUBMISSION CONTROL NO: 167061 _ _ VASOTEC ® IV Page 2 of 30 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................................ 3 SUMMARY PRODUCT INFORMATION .............................................................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................................................... 3 CONTRAINDICATIONS ......................................................................................................................................... 3 WARNINGS AND PRECAUTIONS ........................................................................................................................ 4 ADVERSE REACTIONS ......................................................................................................................................... 7 DRUG INTERACTIONS ........................................................................................................................................ 13 DOSAGE AND ADMINISTRATION .................................................................................................................... 14 OVERDOSAGE ...................................................................................................................................................... 15 ACTION AND CLINICAL PHARMACOLOGY ................................................................................................... 15 STORAGE AND STABILITY ................................................................................................................................ 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................... Կարդացեք ամբողջական փաստաթուղթը